The Fox Chase Chemical Diversity Center Announces that it Has Been Awarded a Small Business Phase I STTR Grant Entitled DC-SIGN Inhibitors for the Treatment of HIV Infection for $300,000.
Doylestown, PA. July 22, 2013- FCCDC is pleased to announce that it has been awarded a small business Phase I STTR grant entitled DC-SIGN Inhibitors for the Treatment of HIV Infection (R41 AI106719-01, $300,000), together with the laboratories of Profs. Pooja Jain and Zafar Khan of the Drexel University College of Medicine.